Navigation Links
Panel blasts federal nanotech risk research strategy
Date:12/10/2008

Washington, DC A National Research Council (NRC) committee today issued a highly critical report describing serious shortfalls in the Bush administration's strategy to better understand the environment, health and safety (EHS) risks of nanotechnology and to effectively manage those potential risks.

The report, Review of the Federal Strategy to Address Environmental, Health, and Safety Research Needs for Engineered Nanoscale Materials, calls for a significantly revamped national strategic plan that will minimize potential risks so that innovation will flourish and society will reap nanotechnology's benefits.

Project on Emerging Nanotechnologies (PEN) Director David Rejeski maintains the "lessons learned" in the NRC report offer a silver lining that will help guide the administration of President-elect Barack Obama.

"It is disappointing that the Bush administration did not listen to PEN experts and repeated calls from nanotech industry and congressional leaders from both parties for an improved and revamped risk research plan for nanotechnology. Their delay has hurt investor and consumer confidence. It has gambled with public health and safety. It has jeopardized the $14 billion investment governments and private industry have made in this technology and its great promise for huge advancements in health care, energy and manufacturing. But I am encouraged that the NRC assessment will provide a roadmap for the next administration to make up for this lost time. It's time to get the job done and to get it done right," says Rejeski.

The risk research plan developed under the National Nanotechnology Initiative (NNI) has been widely criticized by consumer groups, chemical industry representatives and congressional lawmakers from both major parties as lacking a clear vision and the resources necessary to improve understanding of the potential risks posed by nanomaterials.

The new NRC report, written by a highly regarded team of top U.S. experts, echoes PEN experts' statements, analysis and research since 2005. PEN's work has extensively documented the need for a greatly improved government risk research strategy, more transparency and priority-setting in federal risk research funding, and a new mechanism for coordinating research.

The NRC document states that the NNI strategy "contains conflicting statements about the use of fiscal year 2006 research projects to evaluate research needs."

PEN experts have repeatedly stated that the risk-relevant research investment by the federal government was far less than the figures cited by the Bush administration. Most recently, PEN staff also developed federal risk-research funding options for moving forward (see: www.nanotechproject.org/ehsfunding/).

The new NRC report also echoes PEN's calls for an improved mechanism for conducting research. As many as 18 federal agencies -- including the Defense Department, the Environmental Protection Agency and the Food and Drug Administration -- are under the umbrella of the NNI's environment and health implications working group, making coordinating research a challenging task.

PEN testimony before the House Committee on Science and Technology in both 2007 and 2008 provided detailed recommendations for a new mechanism for organizing federal nanotechnology research that would improve coordination among agencies. The principal recommendation is to replace the current bottom-up collection of individual agency research agendas and budgets with a top-down, highly focused and fully-funded strategy that addresses the risk research priorities of a rapidly commercializing new technology.

"The NRC report explicitly says that the federal plan 'does not have the essential elements of a research strategy,'" Rejeski says. "That is if nothing else a clear sign that it is time for a new start."


'/>"/>

Contact: Colin Finan
colin.finan@wilsoncenter.org
202-691-4321
Project on Emerging Nanotechnologies
Source:Eurekalert

Related biology technology :

1. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
2. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
3. Bradmer sponsors physician panel to raise awareness of brain cancer treatments
4. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
5. Endovascular Forum Inc.s President to Participate in Health 2.0 Northeast Panel
6. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
7. Vermillion Announces Receipt of NASDAQ Panel Decision
8. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
9. Expert Neurology Panel Weighs Impact of New Reports of PML in Multiple Sclerosis Patients on Tysabri
10. Arbitration Panel Issues Ruling in Distribution Dispute
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... CA (PRWEB) , ... December 01, 2016 , ... ACEA ... from its Phase I/II clinical trials for AC0010 at the World Conference on Lung ... to providing an update on the phase I/II clinical trials for AC0010 in patients ...
(Date:12/2/2016)... KING OF PRUSSIA, PA (PRWEB) , ... December 01, 2016 , ... ... clinical research is through industry-wide collaboration, standardization and a beautiful technology experience. All three ... which convened more than 100 clinical trial leaders from over 40 sponsor, CRO and ...
(Date:12/2/2016)... -- The immunohistochemistry (IHC) market is projected to ... 7.3% during the forecast period of 2016 to 2021 dominated by ... for the largest share of immunohistochemistry (IHC) market, by end user. ... , , ... spread across 225 pages, profiling 10 companies and supported with 181 ...
(Date:11/30/2016)... , Nov. 30, 2016 /PRNewswire/ - Portage Biotech ... Securities Exchange: PBT.U), is excited to announce the ... focused on developing preclinical ophthalmology assets through proof ... potent anti-inflammatory created by Portage Pharmaceuticals Limited and ... with ocular surface and anterior segment diseases. This ...
Breaking Biology Technology:
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... LiveWire Healthcare and Life Sciences Awards as "Most ... off an unprecedented year of recognition and growth for ... over 15 years. iMedNet ™ ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):